BIOFIRE Respiratory Panel 2.1 (RP2.1)
Biofire Diagnostics · Decision date Sep 22, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K263054 on September 22, 2026, covering the BIOFIRE Respiratory Panel 2.1 (RP2.1) from Biofire Diagnostics, a Class II device under 21 CFR 866.3981 with product code QOF in the Microbiology panel. The submission was a Special 510(k) received September 1, 2026, filed against the submitter's own previously cleared RP2.1 (DEN200031).
The cleared change is a pouch module software update that expands the melting temperature window for the Parainfluenza virus 3 target analyte, prompted by post-market identification of a PIV3 sequence variant with Tm values outside prior interpretation criteria. The decision summary states the indications for use and fundamental scientific technology are unchanged, and that reanalysis of clinical and analytical data with the modified software showed performance consistent with the previously cleared device. The review document does not disclose the numeric Tm window, variant prevalence, or reanalysis results.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Sep 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263054
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Biofire Diagnostics
- Product code
- QOF
- Decision code
- SESE
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.
- Applicant
- Biofire Diagnostics
- Product code
- QOF
- FDA device class
- 2
FDA decision timeline
K263054 received
Application receipt date recorded by FDA.
K263054 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| GenMark Diagnostics, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
Xpert Xpress CoV-2/Flu plusK263333 | Cepheid | 510(k) clearance | Oct 22, 2026 | FDA |
Xpert Xpress CoV-2/Flu plusK263120 | Cepheid | 510(k) clearance | Oct 2, 2026 | FDA |
Xpert Respiratory PanelK261336 | Cepheid | 510(k) clearance | Sep 25, 2026 | FDA |
| Baebies, Inc. | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biofire Diagnostics
- Headquarters
- Not reported
- Brand website
- biofiredx.com
- FDA applicant address
- Salt Lake City, UT
Sources and methodology
- Original FDA record: K263054
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


